GlassScriptPhysician profile
Galina Karpenko
NPI 1639237100
$5,765.66
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $508 · 2021: $830 · 2022: $994 · 2023: $1,364 · 2024: $634 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.55 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $605.77 | 2019-2025 | Menopur |
| Sumitomo Pharma America, INC. | $590.93 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $417.85 | 2019-2023 | Balcoltra |
| Pfizer INC. | $396.63 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $388.29 | 2021-2025 | |
| Astellas Pharma US INC | $377.98 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $287.93 | 2021-2022 | |
| Evofem Biosciences, INC. | $169.49 | 2021-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $159.20 | 2019-2025 | Intrarosa, Femlyv |
| Exeltis, USA INC. | $144.63 | 2019-2023 | Slynd |
| Lupin INC. | $135.98 | 2019-2020 | |
| Daiichi Sankyo INC. | $121.90 | 2020-2022 | |
| Agile Therapeutics, INC. | $119.87 | 2021-2023 | Twirla |
| Vertical Pharmaceuticals, LLC | $100.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $97.40 | 2023 | Myrisk |
| Mission Pharmacal Company | $79.26 | 2019-2020 | |
| Scynexis, INC. | $61.78 | 2022 | |
| Ascend Therapeutics US, LLC | $61.27 | 2021-2023 | |
| Allergan, INC. | $60.40 | 2019-2020 | |
| Emd Serono, INC. | $57.38 | 2019 | |
| Coopersurgical, INC. | $56.21 | 2020-2021 | |
| Therapeuticsmd, INC. | $45.15 | 2019-2022 | |
| Duchesnay USA Incorporated | $43.30 | 2019 | |
| Hologic Sales and Service, LLC | $18.90 | 2019 | |
| Virtus Pharmaceuticals LLC | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Galina Karpenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.